Immune cell therapy for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests a new immune cell therapy (GT201) combined with a PD-1 inhibitor for advanced head and neck cancer. It aims to see if your own immune cells, collected from your tumor, can be boosted to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head or neck cancer that has come back or spread, and you've had 2 or fewer prior treatments.
- You are between 18 and 70 years old.
- You are healthy enough to have a small surgery to remove a piece of your tumor (about the size of a grape).
- Your major organs (heart, lungs, liver, kidneys, blood) are working well.
- You don't have active infections, autoimmune diseases, or uncontrolled bleeding risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This trial compares two different treatments for people who have already had surgery for advanced head and neck cancer and responded very well to chemotherapy plus immunotherapy before surgery. It tests whether continuing with immunotherapy or receiving radiation therapy is better at preventing the cancer from coming back.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
This trial tests a combination of three immunotherapy drugs (PD-L1 t-haNK, NAI IL-15sa, and cetuximab) for people with head and neck squamous cell carcinoma that has spread or cannot be cured. The goal is to see if this treatment can shrink tumors or slow the disease.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.